A new analysis of 4210 patients who had an acute ischemic stroke suggests that the blood thinner tirofiban may help more people recover independently. The review combined results from multiple studies and found that patients given tirofiban were 13% more likely to achieve functional independence at 90 days compared to those receiving standard care. They were also 17% more likely to have an excellent outcome with no or minimal disability.
However, the benefit came with a trade-off. Tirofiban increased the risk of any intracranial hemorrhage by 25%. The rate of symptomatic bleeding in the brain was not significantly different between groups, but the overall bleeding risk was higher. There was no difference in mortality.
The evidence is considered moderate, meaning the findings are promising but not definitive. The analysis included a mix of studies, and the authors caution that the results should be interpreted carefully. They call for more high-quality trials to confirm both the effectiveness and safety of tirofiban before it becomes a routine part of stroke care.
For now, tirofiban appears to offer a potential benefit for stroke recovery, but the increased bleeding risk means it is not yet ready for widespread use. Patients and doctors should discuss the balance of risks and benefits on a case-by-case basis.
